Loading…
Loading grant details…
| Funder | NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES |
|---|---|
| Recipient Organization | Mayo Clinic Rochester |
| Country | United States |
| Start Date | Sep 20, 2024 |
| End Date | Aug 31, 2026 |
| Duration | 710 days |
| Number of Grantees | 2 |
| Roles | Co-Investigator; Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 11057087 |
ABSTRACT More than 10 million Americans are affected by osteoporosis, and an estimated 40 million Americans are at risk of osteoporosis from decreased bone mass. In addition to primary osteoporosis affecting post-menopausal women and the elderly, secondary osteoporosis from conditions such as plasma cell disorders, lupus and
hyperparathyroidism also increases the risk of skeletal fractures. The spine is a prevalent site for osteoporotic fractures resulting in substantial morbidity due to debilitating consequences such as pain and immobility. Current diagnostic approach for osteoporosis evaluation such as dual-energy x-ray absorptiometry (DXA) lack
the spatial resolution to characterize trabecular microarchitecture, a crucial marker of bone quality. Considering the high socioeconomic burden related to skeletal fragility, there is an unmet clinical need to develop a quantitative bone characterization technique that can comprehensively measure cortical and trabecular
microstructures in vivo. Photon-counting detector (PCD) CT has been recently introduced for clinical use. We have demonstrated numerous technical and clinical benefits of PCD-CT for musculoskeletal imaging. A single PCD-CT scan offers both high spatial resolution (110 µm) and spectrally resolved x-ray data which are beneficial for characterizing
trabecular morphometry and volumetric bone density. The long-term goal of our work is to extract imaging biomarkers of bone quality for routine assessment of skeletal fragility and guide timely initiation and monitoring of pharmacologic therapies in patients at high risk of osteoporotic fractures. The objective of this proposal is to
demonstrate the clinical utility of PCD-CT in characterizing bone quality in the vertebrae of patients undergoing pharmacologic therapy for osteoporosis. We propose to meet this objective by first developing and validating a quantitative spine PCD-CT imaging methodology using cadavers and compare the results to a high-resolution
reference standard (micro-CT) in Aim 1, and clinically translate the imaging methodology in Aim 2 to demonstrate in vivo bone quantification in osteoporotic patients. The significance of our proposed technique is that it will enable accurate characterization of bone quality on a clinically available CT system for direct or
opportunistic bone quality assessment.
Mayo Clinic Rochester
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant